Skip to main content
31 cover
Quality of LifeAllArticleYARN

What Cancer Screenings Should You Get? A Practical Guide by Age, Sex, and Risk

What cancer screenings should I get? Start with your age and sex, see where European programmes differ, learn when family history or smoking changes the plan, and bring the right questions to your next appointment.

Published:
Updated:

Key takeaways

  • A 2022 Council of the EU recommendation sets screening ages and tests for breast, cervical and bowel (colorectal) cancer [1]. Those are the three to look at first.
  • The Council's benchmark ages are 50 to 69 for mammography (with 45 to 74 suggested), 30 to 65 for HPV testing, and 50 to 74 for stool testing [1]. Your country's programme may use different ages, so check it.
  • For lung and prostate cancer, the Council asks countries to take a stepwise approach [1]. Ask your country's programme what it offers.
  • If a close relative had cancer young, you carry an inherited gene change, or you've smoked heavily, tell your doctor. Your plan may be different.
  • Use this guide to prepare for a conversation with your doctor, not to replace one. Then check the details with your country's programme.

Why cancer screening advice feels so confusing

If you've ever typed "what cancer screenings should I get" into a search bar, you probably came away with more questions than answers. Your doctor mentions a colonoscopy. A news story says mammograms start earlier now. A friend swears by a full-body scan she saw advertised. An online quiz wants your email before it tells you anything.

The confusion is fair. The Council of the EU, the European Commission's guideline groups and specialist medical societies each publish their own advice [1], [2], [3]. The Council's recommendation is addressed to member states [1]. To find out what you'll actually be invited to, ask your country's programme.

None of this means anyone is being careless. The Council's own text names both sides of the trade-off: fewer deaths from the disease or fewer invasive cancers on one side, and false alarms, missed cancers and treatment you didn't need on the other [1].

The other reason it feels muddy is that average risk and higher risk follow different rules [1]. A 42-year-old with no family history and a 42-year-old who carries a BRCA1 gene change don't follow the same plan [2], [4].

So instead of piling every guideline on you, this guide follows your situation. Find your age. Add your sex and your family history. That tells you which screenings apply to you.

Three screenings come with clear EU ages and tests: breast, cervical and bowel [1]. The table gives those benchmarks. Lung and prostate are in it too, but as you'll see, they work differently.

CancerWho it's forEU benchmark agesMain testHow oftenSource
BreastWomen50 to 69 recommended; 45 to 74 suggestedMammographyEvery 2 years at 50 to 69 (suggested over every 3)[1], [2]
CervicalWomen and anyone with a cervix30 to 65 (the Commission's guideline group suggests starting at 25)HPV testEvery 5 years or more[1], [5]
ColorectalWomen and men50 to 74FIT stool test, then colonoscopy if positiveAsk your programme[1]
LungHeavy smokers and heavy ex-smokersNo routine recommendation; countries asked to explore it step by stepLow-dose CT scanAsk your programme[1]
ProstateMenNo routine recommendation; the EAU says to offer early PSA testing to well-informed men from 50PSA test, with MRI as a follow-upDecide with your doctor[1], [6]

31. 2 cancer screening

Breast cancer screening

The standard test is a mammogram, an X-ray image of the breast. The Council of the EU recommends mammography for women aged 50 to 69 and suggests a lower age limit of 45 and an upper limit of 74 [1]. The European breast guidelines from the European Commission's Joint Research Centre recommend mammography screening for women aged 50 to 69 within an organised programme, and suggest it for women aged 45 to 49 and 70 to 74 [2].

For women aged 50 to 69 at average risk, the guidelines suggest a scan every two years rather than every three, and they recommend against screening every year [2]. Your country's programme may use different ages or intervals, so check what it offers.

Dense breast tissue can mask cancers on a mammogram, which lowers the test's sensitivity [3]. In 2022, the European Society of Breast Imaging (EUSOBI) recommended offering breast MRI to women with extremely dense breasts, although how far that goes in practice depends on local resources [3].

Cervical cancer screening

The Council names HPV testing, which looks for human papillomavirus, as the preferred cervical screening test, for women aged 30 to 65 with five years or more between tests [1]. It also suggests that countries consider offering self-sampling kits, especially to people who don't respond to invitations [1].

The Commission's cervical guideline group is more specific. It recommends HPV testing over cytology (the smear test) and says existing cytology programmes should transition to HPV-based screening [5]. It recommends against screening people under 25 who have no symptoms, suggests starting at 25 rather than 30 provided that people with a positive HPV result get effective follow-up testing, and recommends carrying on to age 64 rather than stopping at 50 [5]. After a negative HPV test, it suggests waiting five years if you're under 40, and seven years from 40 to 64 if you've never had a positive HPV result [5]. Your country may not have switched yet, so ask which test and interval it uses.

Vaccination can change the schedule for some groups. Where at least 75% of a birth cohort (everyone born in the same years) was vaccinated against HPV, the working group suggests starting HPV screening at 30, with 10 years between negative tests. Where coverage is below 50%, it points back to the general-population recommendations [7].

Colorectal cancer screening

For bowel cancer, the Council considers the faecal immunochemical test (FIT), a stool test, the preferred screening test for people aged 50 to 74, with a follow-up colonoscopy for anyone referred after a positive result [1].

A 2026 report from the European Commission's Joint Research Centre found that 22 member states have organised, population-based bowel screening programmes, and that 18 countries use FIT as the main test. The most common target age range is 50 to 74, used in 10 member states [8].

Bowel cancer is also becoming more common in younger adults in Europe, according to a 2019 study of cancer registry data on 143.7 million people aged 20 to 49 in 20 European countries [9]. The authors saw no argument for starting screening at 45 in Europe, but said that if the trend continues, screening guidelines may need to be reconsidered [9].

Screening is for people without symptoms. If you notice blood in your stool or a lasting change in your bowel habits at any age, see a doctor instead of waiting for an invitation.

Read next · Quality of LifeHow to Sleep with a Chemo Port: Comfort Tips That Actually WorkNobody warns you about how hard it is to sleep with a chemo port. Your oncology team covered the medical basics — keep it clean, watch for infection — but skipped the part where you're staring at the ceiling at 2 AM trying to figure out which way to lie down. This guide is the practical version: the best sleeping positions, pillow tricks that actually work, what to do when you're connected to a pump overnight, and what the first week feels like compared to month two. You'll sleep again — let's get you there faster.

Cancer screenings by age, decade by decade

If the cancer-by-cancer view feels like a lot, age is an easier way in. Here's what to think about in each decade at average risk. If your family history is strong, ask your doctor whether your dates should move earlier.

In your 20s

Cervical screening isn't recommended before 25: the European guideline group recommends against it for people under that age who have no symptoms [5]. This decade is also a good time to find out your family history while the relatives who know it are around to ask. That conversation can change what you're offered later.

In your 30s

Cervical screening carries on. The guideline group suggests five years between negative HPV tests while you're under 40 [5]. If a close relative was diagnosed with breast or bowel cancer young, this is a good decade to ask whether you should start those screenings early.

In your 40s

This is the pivot. For women at average risk, the European breast guidelines suggest not screening at 40 to 44 and suggest mammography from 45 [2]. Check whether your country invites you at 45 or waits until 50. The EU benchmark for bowel screening starts at 50 [1]. Among member states, the most common range is 50 to 74 [8]. If you don't have a regular doctor, your 40s are a good time to find one.

In your 50s

Often the fullest decade. Mammography, HPV testing and FIT can all be in play, because their EU age ranges overlap here [1]. Lung screening can enter the picture if you smoke or used to smoke heavily and live somewhere that offers it. For men, the EAU recommends offering early PSA testing to well-informed men from 50 [6].

In your 60s and beyond

Some screenings wind down. Breast screening is recommended to 69 and suggested to 74, and bowel screening runs to 74 [1]. For cervical screening, the guideline group suggests stopping from 65, unless you've never been screened or haven't had an HPV test in the last 10 years [5]. For women aged 70 to 74, the European breast guidelines say continued screening should be guided by life expectancy [2]. Ask your doctor how that applies to you.

If you're a man, three things apply: bowel screening, lung screening if you smoke or used to smoke heavily and your country offers it, and a decision about prostate testing. Bowel screening works for men as it does for women, with FIT from 50 to 74 [1]. Prostate screening is the one that needs a conversation.

Prostate screening (PSA): a decision, not a default

PSA stands for prostate-specific antigen, and the decision about testing for it isn't simple. Given the preliminary evidence and the significant amount of opportunistic screening already going on (testing outside an organised programme), the Council asks countries to consider a stepwise approach, including piloting and further research, based on PSA testing with an MRI scan as a follow-up test [1].

The European Association of Urology (EAU) recommends offering early PSA testing to well-informed men at elevated risk: from 50; from 45 with a family history of prostate cancer before 60; from 45 if you're of African descent; and from 40 if you carry a BRCA2 gene change [6].

Why the hedging? In the large European ERSPC trial, which included more than 182,000 men, screening reduced deaths from prostate cancer [6]. But PSA screening also brings overdiagnosis, which means finding a cancer that would never have caused symptoms in your lifetime, and overtreatment of low-risk prostate cancer, with treatment-related side effects [1], [6]. Anyone who tells you the answer is obvious either way is oversimplifying.

Testicular and skin awareness for men

Testicular and skin cancer sit outside the screenings covered here. For both, the practical move is knowing what's normal for your body, and getting a new lump, a change in a testicle or a mole that has changed looked at by a doctor.

Lung cancer screening: who actually qualifies

Lung screening is easy to misread, because it sounds like it should be for everyone who has ever smoked. The Council of the EU's 2022 recommendation is narrower. It asks countries to explore low-dose CT screening step by step, starting with heavy smokers and people who used to smoke heavily, and it describes the evidence so far as preliminary [1].

England shows what a rollout can look like. The NHS website says that people aged 55 to 74 who have ever smoked may be offered a lung health check, and that checks are currently only available in some parts of England [10]. NHS England reports that its lung screening programme has reached half of England's most at-risk people, and that a nationwide rollout is planned by 2030 [11].

You'll also find US rules online. The US Preventive Services Task Force (USPSTF) recommends yearly low-dose CT for adults aged 50 to 80 who have a 20 pack-year smoking history and currently smoke or quit within the past 15 years [12]. That is US guidance, and European criteria differ: England, for example, looks at people aged 55 to 74 who have ever smoked [10].

A pack-year is one pack of 20 cigarettes a day for a year [12]. So 20 pack-years could be a pack a day for 20 years, or two packs a day for 10. To work out your own, see our guide on Pack-Years Explained: Formula, Examples and Health Risks, which walks you through the formula.

If your country offers a scan, talk through what it can and can't tell you before you book. If you smoke, ask for stop-smoking support at the same visit. The US task force notes that screening does not prevent most lung cancer deaths, so quitting remains essential [12].

Quick self-check Does your country or region run lung screening or a pilot? Do you smoke now, or did you smoke heavily in the past? Two yeses mean it's worth asking your doctor whether you qualify.

31.3 cancer screening

When family history changes the plan

The ages and tests above are for people at average risk. Family history can move you out of that group. For people at increased risk, the Council asks countries to consider specific programmes with wider target groups and more intensive screening [1].

The National Institute for Health and Care Excellence (NICE) offers one example of how this works. It recommends different surveillance for women of different ages and levels of risk [4]. For women at moderate risk, that means a yearly mammogram from 40 to 49 [4]. For women with a BRCA1 or BRCA2 gene change, it means a yearly MRI and possibly a yearly mammogram from 30 to 39, then a yearly mammogram and a yearly MRI from 40 to 49 [4]. Your own country may have different rules, so ask your doctor what applies where you live.

For prostate cancer, the EAU brings the starting age for PSA testing forward to 45 with a family history of prostate cancer before 60, and to 40 if you carry a BRCA2 gene change [6].

To learn which cancers can run in families, how genetic counselling and testing fit in, and what that means for your own risk, see our guide on What Type of Cancers Are Hereditary? A Guide to Genetic Risks and Prevention.

The table below turns what you know about your family into a next step.

What you know about your familyWhat to do with it
A parent, brother, sister or child had cancer at a young ageTell your doctor which cancer and how old they were
Several relatives on the same side of the family had the same cancerWrite down who, which cancer and when, then ask your doctor what it means for you
A gene change such as BRCA1 or BRCA2 runs in your familyAsk about genetic counselling and a surveillance plan, which can include earlier MRI and mammograms [4]
You've had cancer yourself, or radiotherapy to the chestSay so when you book any screening
You're in a group with higher risk of one cancer, such as men of African descent and prostate cancerAsk about earlier PSA testing, which the EAU recommends offering from 45 [6]
You don't know your family historyAsk relatives what they remember, and tell your doctor what you couldn't find out

If any of these sounds like your family, ask your doctor whether a referral for genetic counselling makes sense.

What screening can and can't do for you

We owe you honesty here: screening has downsides as well as benefits, and you should hear both. Screening makes it possible to find cancer at an early stage, or possibly even before it becomes invasive, and the Council's main measure of whether screening works is fewer deaths from the disease or fewer invasive cancers [1].

The downsides are real. A false alarm, which is a result that suggests cancer when there isn't any, can cause anxiety and may mean more tests. A missed cancer can falsely reassure you and delay your diagnosis. And overdiagnosis means finding a cancer that would never have caused symptoms in your lifetime, which can lead to treatment you didn't need [1].

None of this is an argument to skip screening. Recommendations are tied to age and risk, and the Council asks countries to present benefits and risks, including overdiagnosis and overtreatment, in a way you can understand [1]. If a doctor hesitates to order a test for you, ask what balance of benefit and harm they're weighing.

Newer tests you'll hear about: multi-cancer blood tests

Some blood tests aim to screen for many cancers at once. They're called multi-cancer early detection (MCED) tests, and Galleri is one of them [13], [14].

NHS-Galleri in England, described by its team as the world's first randomised controlled trial of an MCED test, involved more than 142,000 volunteers aged 50 to 77 [13], [14]. In September 2026, the trial team announced that its first full results had been published in the New England Journal of Medicine and Nature Medicine [13].

The team's summary says there was no difference overall in the number of people diagnosed with late-stage cancer, so the trial did not meet its main goal [13]. In the test group, fewer people were diagnosed with the most advanced cancers, more early stage cancers (stage 1 and 2) were found, and fewer people were diagnosed in an emergency [13]. Around one in 100 people had a positive test result, and around half of those were diagnosed with cancer [13].

More results will be available in the coming months and years, and the NHS and other health organisations will review the trial in detail to understand how this type of test could be used in the future [13]. For now, treat these tests as something to ask your doctor about, not a replacement for your mammogram, HPV test or bowel screening.

How much do cancer screenings cost?

We can't give you one price for Europe, so ask before you book. Check what your country's programme covers, what your insurance covers and what you'd pay for a test you arrange yourself.

What the Council does ask is that countries take action to ensure equitable access to screening, and that people with a positive result get adequate, timely and complementary diagnostic procedures and treatments [1]. Before you book a test outside a programme, such as a private scan or a multi-cancer blood test, ask what it costs and whether your insurer reimburses it.

Is cancer screening covered by insurance or public health systems?

Check what your country's health system and your insurer cover before you book. Your national screening programme's website, your GP or your health insurer can tell you. Ask three things: whether the invitation test is covered in full, how follow-up after an abnormal result is handled, and whether tests you arrange yourself are reimbursed.

The Council recommends that countries make sure everyone targeted by a screening programme is invited to take part [1]. If you're in the target group and haven't heard anything, ask your GP.

How to find cancer screening tests near you

Start with your GP or family doctor. They know your history, and they can refer you or explain how your country's programme works.

If your country runs a national programme, watch for an invitation. The Council recommends that countries aim to set up a systematic call and recall system [1]. When it arrives, answer it.

No regular doctor? Contact your national or regional screening programme or your local health authority. When you book, ask whether the test is part of the programme, what it will cost you and how you'll get your results. Those three answers save a lot of confusion later. You'll find more guides in the Beat Cancer resource library.

Screening is for people without symptoms. If you have symptoms, see a doctor now instead of waiting for an invitation.

Questions to bring to your next appointment

This is the section to screenshot or print. In the room, it's easy to forget what you meant to ask.

  • Which cancer screenings do you recommend for someone of my age, sex and history, and why?
  • Am I at average risk, or does something in my history change the plan?
  • When should I start each one, and how often should I repeat it?
  • What are the benefits and the downsides of this screening for someone like me?
  • Does my country offer lung screening, and do I qualify based on my smoking history?
  • Is this test covered, and could the follow-up cost me anything?
  • When can I stop each screening?

You don't have to ask them all. Pick the ones that matter most, and bring someone along if it helps you remember the answers.

Your next move

Four facts about you do most of the work: your age, your sex, your family history and your smoking history. Write them down and match them against the sections above. Then book one appointment, or answer one screening invitation, and bring your questions.

If you take one thing from this guide, make it this: the most useful way to answer "what cancer screenings should I get" is a specific conversation with someone who knows your history. This guide gets you ready for it. It can't replace it.

References

[1] Council of the European Union. (2022, November 29). Council Recommendation on strengthening prevention through early detection: A new EU approach on cancer screening replacing Council Recommendation 2003/878/EC (Document No. 14770/22). https://data.consilium.europa.eu/doc/document/ST-14770-2022-INIT/en/pdf

[2] European Commission Joint Research Centre. (n.d.-a). Screening ages and frequencies. In European guidelines on breast cancer screening and diagnosis. Cancer Screening, Diagnosis and Care. Retrieved November 15, 2026, from https://cancer-screening-and-care.jrc.ec.europa.eu/en/ecibc/european-breast-cancer-guidelines?topic=63&usertype=60#guideline

[3] European Society of Breast Imaging. (2022, March 8). EUSOBI recommends MRI screening in women with extremely dense breasts. https://www.eusobi.org/news/eusobi-recommendation-breast-cancer-screening-women-with-extremely-dense-breasts/

[4] National Institute for Health and Care Excellence. (n.d.). Early detection of breast cancer by surveillance. Retrieved November 15, 2026, from https://www.nice.org.uk/guidance/cg164/ifp/chapter/Early-detection-of-breast-cancer-by-surveillance

[5] European Commission Joint Research Centre. (n.d.-b). General population: Screening tests, age, and interval. In European guidelines on cervical cancer screening and diagnosis. Cancer Screening, Diagnosis and Care. Retrieved November 15, 2026, from https://cancer-screening-and-care.jrc.ec.europa.eu/en/ec-cvc/european-cervical-cancer-guidelines?topic=328&usertype=327#guideline

[6] European Association of Urology. (2026). Diagnostic evaluation. In EAU guidelines on prostate cancer. Retrieved November 15, 2026, from https://uroweb.org/guidelines/prostatecancer/chapter/diagnostic-evaluation

[7] European Commission Joint Research Centre. (n.d.-c). HPV-vaccinated birth cohorts: Screening ages and intervals. In European guidelines on cervical cancer screening and diagnosis. Cancer Screening, Diagnosis and Care. Retrieved November 15, 2026, from https://cancer-screening-and-care.jrc.ec.europa.eu/en/ec-cvc/european-cervical-cancer-guidelines?topic=359&usertype=327#guideline

[8] Baldacchino, S., Stănică, L., Stathopoulou, A., Alexandru, A.-C., Garcia Escribano, M., Amato, O., & Janusch Roi, A. (2026). Report on the organisation of colorectal cancer care services in Europe (EUR 40492). Publications Office of the European Union. https://publications.jrc.ec.europa.eu/repository/handle/JRC143926

[9] Vuik, F. E. R., Nieuwenburg, S. A. V., Bardou, M., Lansdorp-Vogelaar, I., Dinis-Ribeiro, M., Bento, M. J., Zadnik, V., Pellisé, M., Esteban, L., Kaminski, M. F., Suchanek, S., Ngo, O., Májek, O., Leja, M., Kuipers, E. J., & Spaander, M. C. W. (2019). Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut, 68(10), 1820-1826. https://pmc.ncbi.nlm.nih.gov/articles/PMC6839794/

[10] National Health Service. (2023, March 27). Lung cancer screening. Retrieved November 15, 2026, from https://www.nhs.uk/tests-and-treatments/lung-cancer-screening/

[11] NHS England. (n.d.). Supermarket scans spotting thousands of cancers [News]. https://england.nhs.uk/2026/05/supermarket-scans-spotting-thousands-of-cancers/

[12] U.S. Preventive Services Task Force. (2021, March 9). Lung cancer: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening

[13] NHS-Galleri Trial. (2026a, September 23). First full results from the NHS-Galleri trial published in leading journals [Trial update]. https://www.nhs-galleri.org/trial-updates/first-full-nhs-galleri-results-published-in-leading-journals

[14] NHS-Galleri Trial. (2026b, May 30). NHS-Galleri trial reports fewer diagnoses of the most advanced cancers [Trial update]. https://www.nhs-galleri.org/trial-updates/nhs-galleri-trial-reports-fewer-diagnoses-of-the-most-advanced-cancers

This article is for educational purposes only and is not medical advice. Always consult your doctor or another qualified healthcare professional for guidance specific to your situation.

YARN project logo

This content was created during the YARN project, co-funded under the EU4Health Programme in 2025-2028 (Grant Agreement No. 101219053).

Continue reading · Quality of LifeHow to Sleep with a Chemo Port: Comfort Tips That Actually WorkNobody warns you about how hard it is to sleep with a chemo port. Your oncology team covered the medical basics — keep it clean, watch for infection — but skipped the part where you're staring at the ceiling at 2 AM trying to figure out which way to lie down. This guide is the practical version: the best sleeping positions, pillow tricks that actually work, what to do when you're connected to a pump overnight, and what the first week feels like compared to month two. You'll sleep again — let's get you there faster.